(PubMed) Yang SJ, Hwang SY, Choi HY, et al
In this narrative review, we summarise the current evidence on approved GLP-1 RAs and GIP/GLP-1 RAs for T2DM and obesity, focusing on GI adverse events, their frequencies, underlying mechanisms, and clinical significance
This reflects broader market dynamics following FDA approvals and may be influenced by increasing off-label use
For a self-directed person who already knows how they eat and train (or can figure it out for themselves) and just wants reliable, affordable medication, that is a feature
Immunohistochemical staining for epoxide hydrolase in Holtzman rats showed reactivity throughout the liver lobule, whereas microfluorometric determination of binding showed significantly more binding in centrilobular hepatocytes than the mid-lobular and periportal areas (Kawabata et al
: [3][4]